Home › Hemophilia
Hemophilia clinical trials recruiting in the U.S.
28 studies for Hemophilia are recruiting participants at sites across the United States.
Hemophilia is a rare disorder in which the blood does not clot normally. Usually hemophilia usually occurs in males and is inherited. Learn more.
Cities with the most studies
- Indianapolis, IN8 studies
- Los Angeles, CA7 studies
- Seattle, WA6 studies
- Cedar Rapids, IA6 studies
- Philadelphia, PA5 studies
- Sacramento, CA4 studies
- Greenville, NC4 studies
- Atlanta, GA4 studies
- Dallas, TX4 studies
- Tampa, FL4 studies
- Little Rock, AR4 studies
- Orange, CA4 studies
- Kansas City, MO3 studies
- Detroit, MI3 studies
- Chicago, IL3 studies
- San Francisco, CA3 studies
- St. Louis, MO3 studies
- San Antonio, TX3 studies
- Boston, MA3 studies
- Cincinnati, OH3 studies
- Harrisburg, PA3 studies
- Aurora, CO3 studies
By state
- Arkansas4 studies
- California14 studies
- Colorado3 studies
- Florida6 studies
- Georgia4 studies
- Illinois4 studies
- Indiana8 studies
- Iowa6 studies
- Massachusetts3 studies
- Michigan5 studies
- Missouri5 studies
- New York4 studies
- North Carolina6 studies
- Ohio5 studies
- Pennsylvania6 studies
- Texas8 studies
- Washington6 studies
Recently updated studies
TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies
RecruitingObservational study
6 Months · All sexes · Updated Sep 29, 2026 · NCT07692217A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
RecruitingPhase 4
Ages 12 and older · Men · Updated Sep 23, 2026 · NCT06145373A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RecruitingPhase 3
Ages 1 to 17 · Men · Updated Sep 23, 2026 · NCT05611801A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 23, 2026 · NCT07416526Treatment of Hemophilia A Patients With FVIII Inhibitors
RecruitingObservational study
All ages · Men · Updated Sep 23, 2026 · NCT04023019A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 64 · Men · Updated Sep 18, 2026 · NCT07220564A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RecruitingPhase 1/2
Ages 2 to 59 · Men · Updated Sep 11, 2026 · NCT05987449A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT07226206A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 4, 2026 · NCT07416604SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
RecruitingPhase 3
Ages 6 and older · All sexes · Updated Aug 21, 2026 · NCT04563520Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
RecruitingObservational studyHealthy volunteers welcome
Ages 0 to 20 · All sexes · Updated Aug 21, 2026 · NCT04278404ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
All ages · All sexes · Updated Aug 17, 2026 · NCT04398628A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
RecruitingPhase 3
Ages 1 to 11 · Men · Updated Aug 17, 2026 · NCT07285460A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 60 · All sexes · Updated Jul 2, 2026 · NCT06349473Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
RecruitingObservational study
Ages 6 to 19 · All sexes · Updated Jul 2, 2026 · NCT05022459Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RecruitingPhase 3
Ages 1 to 74 · Men · Updated Jul 1, 2026 · NCT05145127A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
RecruitingPhase 1
Ages 12 to 74 · Men · Updated Jun 3, 2026 · NCT06703606Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
RecruitingObservational study
All ages · All sexes · Updated Jun 2, 2026 · NCT03695978Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
RecruitingPhase 3
Ages 18 and older · Men · Updated May 27, 2026 · NCT05568719Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RecruitingPhase 4
Ages 12 and older · Women · Updated May 12, 2026 · NCT05936580Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
RecruitingPhase 4
Ages 12 and older · Men · Updated May 12, 2026 · NCT05935358ATHNdataset Registry
RecruitingObservational study
All ages · All sexes · Updated Apr 21, 2026 · NCT06820515Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
RecruitingPhase 1
Ages 0 to 90 · All sexes · Updated Apr 3, 2026 · NCT05500807Hemophilia A Research Program
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Feb 17, 2026 · NCT07414511SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
RecruitingPhase 4
Ages 12 to 100 · All sexes · Updated Jan 12, 2026 · NCT04647227From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.